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Summary
Background: Peroxisome proliferator-activated receptor-gamma (PPAR-) agonists
are used as anti-diabetic drugs, and their pleiotrophic action has been reported
to improve endothelial function leading to cardioprotective effects. In this study
we evaluated the long-term effect of pioglitazone on cardiac function in diabetic
patients after percutaneous coronary intervention (PCI) by drug-eluting stent (DES).
Methods and results: We investigated 54 diabetic patients who received PCI using
a sirolimus-eluting stent. We excluded cases of acute myocardial infarction. They
were divided into two groups: Group C received only conventional therapy (n = 26)
and Group P received additionally pioglitazone 15mg/day (n = 28). The left ventric-
ular ejection fraction (LVEF) was measured by left ventriculography and analyzed
before and 8 months after PCI. In Group C, LVEF did not change signiﬁcantly: 55.6%
vs. 56.7%, before and after PCI respectively (p = 0.58). However, pioglitazone signiﬁ-
cantly improved LVEF: 54.4% vs. 60.0% (p = 0.014). Multiple linear regression analysis
showed that LVEF was signiﬁcantly related to pioglitazone therapy (p = 0.037). In
particular, the combination of pioglitazone and statin improved LVEF (LVEF 9.6%
with vs. 2.2% without statin).
∗ Corresponding author at: Division of Cardiology, Niigata University Graduate School of Medical and Dental Sciences, 1-754
Asahimachi-dori, Niigata 951-8510, Japan. Tel.: +81 25 227 2185; fax: +81 25 227 0774.
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Conclusions: Pioglitazone improved cardiac function after PCI using SES in diabetic
patients, especially in combination with a statin.
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converting enzyme (ACE) inhibitors, angiotensin II© 2009 Japanese Colleg
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ntroduction
ercutaneous coronary intervention (PCI) is one of
he ﬁrst-line therapies for coronary artery disease
CAD), but it might not lead to improvement of the
ong-term outcome. In particular, cardiac function
emains depressed in diabetics even after relief
f ischemia by PCI [1]. Recently, PCI with a drug-
luting stent (DES), a sirolimus-eluting stent (SES),
as been widely employed with excellent results
2,3]. Although DES has reduced the rate of resteno-
is after PCI, restenosis has been reported to occur
n the range from 6.0% to 8.2% in non-diabetics and
rom 10.1% to 17.6% in diabetics [4,5]. Impaired
ndothelial regeneration at the site of DES implan-
ation is considered to be responsible and it may
ause late stent thrombosis [6,7]. The long-term
utcomes of PCI with DES remain to be elucidated
specially in diabetic patients.
On the other hand, the peroxisome proliferator-
ctivated receptor-gamma (PPAR-) agonist class,
hiazolidinedione (TZD), has been shown to
ecrease the incidence of cardiovascular events in
iabetic patients [8], but its effect on long-term
ardiac function needs to be evaluated.
In this study, we administered one of the TZDs,
ioglitazone, to diabetic patients with CAD treated
ith DES and evaluated its effects on cardiac func-
ion.
atients
ifty-nine diabetic patients with CAD were
ncluded. In this study, all patients met one or
ore of the following criteria: (1) a fasting blood
lucose level ≥126mg/dL; (2) a casual blood glu-
ose level of 200mg/dL; (3) glycated hemoglobin
HbA1c) ≥6.5% or higher; (4) diabetic type on a
5-g oral glucose tolerance test; and (5) receiving
herapy for diabetes mellitus.
All patients had CAD, either stable angina pec-
oris (Canadian Cardiovascular Society class I—IV),
nstable angina (Braunwald class I—III B or C),
ecent myocardial infarction, or previously docu-
ented myocardial infarction. CAD was proven by
oronary angiography (CAG) with coronary artery
tenosis means ≥51% in diameter. The patients with
yocardial infarction were proven to have viable
yocardium by left ventriculography (LVG), stress
r
C
d
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iCardiology. Published by Elsevier Ireland Ltd. All rights
yocardial scintigraphy, or cardiac magnetic reso-
ance imaging (MRI).
The patients received PCI with DES and were
ollowed over 8 months in the standard manner.
atients were excluded if they had: (1) myocardial
nfarction within the previous 24 h; (2) restenosis,
arget lesion revascularization (TLR) or target ves-
el revascularization (TVR) during follow-up; (3) a
ew lesion at other coronary artery during follow-
p; (4) signiﬁcant valvular heart disease; (5) dilated
ardiomyopathy; and (6) severe renal dysfunction
equiring hemodialysis.
ethods
CI procedures using SES were performed electively
n all patients. Prior to PCI, aspirin (200mg) and
iclopidine hydrochloride (200mg) were adminis-
ered. Patients were divided into two groups. The
ontrol group consisted of 29 patients who under-
ent PCI between June 2004 and February 2005 and
ere treated in the conventional manner without
ioglitazone: ‘‘Group C’’. The other group con-
isted of 30 patients who received PCI between
arch 2005 and June 2005 and were treated with
onventional therapy plus pioglitazone 15mg/day:
‘Group P’’.
At baseline, cardiac catheterization was per-
ormed which included LVG, and CAG as well as a
ressure tracing study. From LVG, left ventricular
nd-diastolic volume index (EDVI), left ventricular
nd-systolic volume index (ESVI), and global left
entricular ejection fraction (LVEF) were calculated
n area-length method from RAO view by other radi-
logists.
Catheterization was repeated 8 months after
CI. EDVI, ESVI, and LVEF values were obtained and
ompared between the two groups. Other clinical
ata were also obtained at baseline and 8 months
fter PCI and compared between the two groups.
In addition, we performed multiple linear regres-
ion analysis for change in LVEF (LVEF) witheceptor blockers (ARB), nitrate agents,  blockers,
a antagonists, statins, pioglitazone, and anti-
iabetic agents other than pioglitazone], lesion
ite, baseline LVEF, baseline EDVI, and HbA1c, as
ndependent variables.
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Table 1 Patient characteristics.
Group C (n = 26) Group P (n = 28) p-Value
Age (mean years ±S.D.) 65.5± 10.3 67.6± 8.8 NS
Male (%) 24 (92.3) 21 (75.0) NS
Diagnosis NS
AP (%) 19 (73.1) 17 (60.7)
OMI (%) 5 (19.2) 5 (17.9)
UAP (%) 4 (15.4) 5 (17.9)
RMI(%) 1 (3.8) 3 (10.7)
Riskfactors
Hypertension (%) 15 (57.7) 17 (60.7) NS
Hyperlipidemia (%) 14 (53.9) 13 (46.1) NS
Smoking (%) 18 (69.2) 17 (60.7) NS
Previous MI (%) 6 (23.1) 6 (21.4) NS
Medication
ACEi (%) 10 (38.5) 15 (53.6) NS
ARB (%) 9 (34.6) 7 (25.0) NS
Nitrate (%) 1 (3.8) 5 (17.9) NS
Ca antagonist (%) 8 (30.8) 10 (35.7) NS
-blocker (%) 13 (50.0) 9 (32.1) NS
Statin (%) 12 (46.2) 13 (46.4) NS
Anti-diabetic drug (%) (except pioglitazone) 12 (46.2) 18 (64.3) NS
Sulfonylurea 8 11
-Gl 5 3
Biguanides 3 4
Other 1 0
Insulin 3 3
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Statistical analysis
Numerical data are expressed as mean± S.D. All
statistical analysis was performed using the JMP
program version 5.0.1J for Macintosh (SAS Insti-
tute, Cary, NC, USA). Variables were compared
before and after PCI using the paired t-test,
with a two-sided signiﬁcance level of p < 0.05.
We used the unpaired t-test in the comparison
between group C and P and used the one-way
analysis of variance (ANOVA) in comparison among
groups.
Results
Patient background
In total, 59 diabetic patients underwent SES implan-
tation and LVG analysis both at baseline and
follow-up catheterization. Of these, two patients
in Group C required additional PCI to another ves-
sel due to progression of stenosis at follow-up,
and 1 had progression of valvular heart disease in
T
c
t
Te angina pectoris; RMI, recent myocardial infarction; ACEi,
or blocker; GI, -glucosidase inhibitor.
roup P. 1 patient had dilated cardiomyopathy in
roup C. TVR was noted in 1 patient in Group C.
n the remaining 54 diabetic patients, we analyzed
he clinical characteristics and the long-term out-
omes. They consisted of 28 who were treated with
ioglitazone: Group P, and 26 without pioglitazone
reatment: Group C. There were no side effects of
ioglitazone 15mg/day, such as leg edema, or heart
ailure.
The background of the patients is shown in
able 1. There were no signiﬁcant differences in
ge, gender, diagnosis, risk factors (hypertension,
yperlipidemia, smoking), a history of myocardial
nfarction, or medication. Blood pressure and heart
ate are shown in Table 2. There were also no signif-
cant differences in blood pressure and heart rate
etween the two groups.
aboratory ﬁndingsable 2 shows the changes in the fasting total
holesterol (TC), triglycerides (TG), HDL choles-
erol (HDL-C), and HbA1c levels during this study.
he baseline HbA1c and TG levels showed small
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Table 2 Follow-up clinical data.
Group C (n = 26) Group P (n = 28) p-Value
Systolic BP (mmHg)
Baseline 130.2± 16.8 126.7± 12.7 NS
Follow-up 126.0± 17.7 129.3± 17.6 NS
p-Value (baseline vs. follow-up) NS NS
Diastolic BP (mmHg)
Baseline 74.0± 13.1 70.1± 9.6 NS
Follow-up 70.1± 10.6 71.5± 9.97 NS
p-Value (baseline vs. follow-up) NS NS
HR(beats/min) (beats/min)
Baseline 68.5± 14.0 66.7± 10.3 NS
Follow-up 66.1± 11.5 65.4± 10.9 NS
p-Value (baseline vs. follow-up) NS NS
Laboratory DATA
HbA1c (%)
Baseline 6.87± 1.47 7.65± 2.00 NS
Follow-up 6.41± 0.91 6.70± 1.27 NS
p-Value (baseline vs. follow-up) NS 0.024
TC(mg/dl)
Baseline 191.1± 26.6 185.0± 38.8 NS
Follow-up 184.0± 30.9 181.3± 38.9 NS
p-Value (baseline vs. follow-up) NS NS
TG (mg/dl)
Bliaseline 1581935.1± 93.5 119.0± 43.0 NS
Follow-up 181.5± 114.1 127.8± 71.0 0.048
p-Value (baseline vs. follow-up) NS NS
HDL-C (mg/dl)
Baseline 47.6± 15.2 39.6± 9.54 NS
Follow-up 42.4± 10.9 42.5± 11.4 NS
p-Value (baseline vs. follow-up) NS 0.044
LVG analysis
EDVI (ml/m2)
Baseline 68.9± 22.5 59.0± 12.1 0.048
Follow-up 70.8± 21.4 61.5± 14.8 NS
p-Value (baseline vs. follow-up) NS NS
ESVI (ml/m2)
Baseline 323.3± 183.3 272.2± 122.2 NS
Follow-up 32.2± 18.5 25.3± 13.2 NS
p-Value (baseline vs. follow-up) NS NS
LVEF(%)
Baseline 55.6± 13.8 54.4± 16.1 NS
Follow-up 56.7± 14.2 60.0± 13.3 NS
p-value (baseline vs. follow-up) NS 0.014
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TThese data show the mean± S.D. BP, blood pressure; HR, h
cholesterol; LVG, left ventriculograms; EDVI, end-diastolic vol
ifferences between the two groups, but they were
ot signiﬁcant. TC and HDL-C were not signiﬁcantly
ifferent between the two groups. The HbA1c
evels decreased (p = 0.024) and the HDL-C levels
ncreased (p = 0.044) signiﬁcantly after pioglitazone
reatment, while conventional therapy resulted in
o change in these parameters.
T
l
(
frate; TC, total cholesterol; TG, triglyceride; HDL-C, HDL-
index; ESVI, end-systolic volume index; EF, ejection fraction.
AG ﬁndings
he cardiac catheterization ﬁndings are shown in
able 3. In Group P, culprit lesions involving the
eft circumﬂex coronary artery were more frequent
p = 0.032). However, there were no signiﬁcant dif-
erences in other lesions. There were also no
406 T. Ozawa et al.
Figure 1 Global left ventricular ejection fraction (LVEF) at
for individual patients; large dots show mean values. Vertical
marked differences in the number of treated ves-
sels between the two groups.
Follow-up of LVEF
LVEF before and after PCI are shown in Fig. 1. In
Group C, there was no signiﬁcant increase after
treatment (55.6% at baseline vs. 56.7% at 8 months’
follow-up, p = 0.58). However, in Group P, LVEF sig-
niﬁcantly increased (54.4% vs. 60.0%, p = 0.014),
Table 3 CAG ﬁndings.
C group
(n = 26)
P group
(n = 28)
p-Value
Culprit
LAD 13 (50.0) 14 (50.0) NS
Cx 5 (19.2) 13 (46.4) p = 0.0317
RCA 10 (38.5) 8 (28.6) NS
LMT 1 (3.9) 1 (3.6) NS
other 2 (7.7) 1 (3.6) NS
Number of
target
vessel
1.2± 0.5 1.3± 0.5 NS
Lesion type NS
ACS 7 (26.9) 12 (42.9)
de novo 12 (46.2) 11 (39.3)
restenosis 3 (11.5) 1 (3.6)
CTO 4 (15.4) 4 (14.3)
These data show the mean± S.D. LAD, left anterior descend-
ing artery; Cx, left circumﬂex coronary artery; RCA, right
coronary artery; LMT, left main trunk; ACS, acute coronary
syndrome; CTO, chronic total occlusion.
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uggesting improvement in cardiac function by
ioglitazone.
The results of multiple linear regression analy-
is in 54 diabetic patients are shown in Table 4.
aseline LVEF (p = 0.0017), pioglitazone adminis-
ration (p = 0.037), and the absence of RCA lesion
p = 0.030) correlated with LVEF. There was no
orrelation between LVEF and other parameters.
n addition, the effect of combination therapy
ith pioglitazone and a statin is shown in Fig. 2.
here were no signiﬁcant differences in base-
ine LVEF among the four groups (p = 0.103). Only
ombination therapy with pioglitazone and statin
igniﬁcantly improved LVEF after PCI (51.5% at base-
ine vs. 61.1% at 8 months’ follow-up, p = 0.0066),
nd the absolute increase in LVEF (LVEF) was +9.6%
n the combination therapy group. The LVEF of the
ther three groups did not change signiﬁcantly.
iscussion
he present study showed that low-dose piogli-
azone improved cardiac function after DES in
iabetic patients and such a beneﬁcial effect
as not observed in the patients followed with-
ut pioglitazone (Group C). All patients were free
rom restenosis. By the results of multiple linear
egression analysis, improved LVEF signiﬁcantly cor-
elated with baseline LVEF, non-RCA lesion, and
ioglitazone treatment. Although ACE inhibitor,
RB, and statin alone have already been reported
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Table 4 Multiple linear regression analysis of LVEF in diabetic patients.
ˇ Standard error t p-Value
Baseline LVEF −14.70 4.19 −3.52 0.0017
Pioglitazone 4.83 2.19 2.2 0.037
Statin 2.46 1
Absence of RCA lesion 5.497 2
to improve LV dysfunction, this is not the case in
diabetic patients. Combined therapy of pioglita-
zone and statin was most impressive (Fig. 2).
Pioglitazone is the ﬁrst oral anti-diabetic agent
that has been demonstrated to improve the
hard endpoints (all causes of mortality, non-fatal
myocardial infarction, and stroke) for secondary
prevention after myocardial infarction [8]. TZDs
are assumed to play multiple actions: improve-
ment in endothelial dysfunction [9], increase
in endothelial progenitor cells (EPC), enhance-
ment of EPC differentiation, survival, and function
[10—12], enhancement of angiogenesis [13], sup-
pression of inﬂammation [14], and increase in
the plasma adiponectin level [15]. TZDs have also
been shown to up-regulate the PI3K-Akt signal and
down-regulate MAPK, leading to endothelial repair
[16]. The precise mechanism for improved car-
diac function in diabetic patients is speculative,
but pleiotrophic effects of pioglitazone seem to be
involved [17—20], and seem to explain the bene-
Figure 2 The effect of combination therapy with piogli-
tazone (Pio) and statins (Sta) to the absolute increase in
left ventricular ejection fraction (LVEF). Column bars
show meanLVEF. Vertical bars show S.D.
ﬁ
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.38 2.31 0.030
cial effect on cardiac function as shown by the
resent study.
However, previous studies have not shown
mprovement in LVEF, as assessed by echocar-
iography [21] in patients who did not undergo
evascularization. Others reported that pioglita-
one prevented in-stent restenosis but did not
ffect LVEDVI in diabetic patients who received
are metal stent implantation after acute myocar-
ial infarction [22]. High-dose pioglitazone did not
hange LV remodeling after coronary ligation in
ice [17]. There were some discrepancies between
he previous studies and our study, and we showed
hat patients on low-dose pioglitazone demon-
trated improved cardiac function especially when
t was combined with statins. The combination ther-
py of TZDs and statin has already been shown to
educe the size of infarcted myocardial foci [23],
nd they may play additive effects in improving car-
iac function after DES. Both drugs might relieve
ndothelial dysfunction and oxidative stress after
ES implantation. Since intra-myocardial capillary
ensity has been shown to be decreased in dia-
etic patients compared to non-diabetics [24], the
ffect of either drug on inducing angiogenesis might
esult in favorable long-term results. Microcircula-
ion distal to the site of SES might be improved
s endothelial function improves. Otherwise, the
irect effect of sirolimus [25] may impair endothe-
ial function and suppress LV function even after
elief of ischemia.
In addition, pioglitazone may promote endothe-
ial regeneration via mobilization of EPC, and
revent late stent thrombosis. Thus, in PCI using
ES, combination therapy with pioglitazone and
tatin should be administered to diabetic patients
o achieve secondary prevention and improve car-
iac function.
tudy limitations
his study has some limitations. First, this was an
nblinded, non-randomized, cohort study. Although
e used ‘‘Group C’’ as the historical control,
e did not change the strategy of PCI using SES
etween two groups. Second, LVG analysis was per-
ormed from the RAO view, so mild regional wall
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[408
motion abnormality might have been undetected.
However, we could obtain a global function of LV in
the most accurate way so far.
Conclusion
Pioglitazone, a PPAR- agonist, improved cardiac
function after PCI with DES in diabetic patients. The
combination therapy of pioglitazone and statin can
be indicated in diabetic patients after PCI.
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